All In MedTech

Device Trial Radar · NCT06507423

Performance of the SeptiCyte LAB Test for Antibiotic Stewardship in Mesenteric Ischemia

Study to Evaluate the Performance of the SeptiCyte LAB Test for Antibiotic Stewardship in Mesenteric Ischemia

Last checked: Nov 19, 2026Latest source record: Apr 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

15

Actual

Start

Aug 1, 2024

Primary completion

Sep 1, 2024

Study completion Nov 1, 2024

Sponsor

Lead sponsor
Central Hospital, Nancy, FranceAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 18, 2024

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
All sexes, from 18 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will help determine whether the SeptiCyte LAB test can accurately differentiate between SIRS and actual infections in postoperative patients, potentially reducing unnecessary antibiotic use and improving patient outcomes in cases of acute mesenteric ischemia

Conditions

  • Acute Mesenteric Ischemia
  • Sepsis Bacterial
  • Intra-abdominal Infection
  • Digestive Inflammation

Interventions

  • Septicyte Lab Test pre operativeDevice

    SeptiCyte® technology uses proprietary biomarker signatures to assess the response of a patient's immune system to infections. It provides a score which can be used to differentiate sepsis from systemic inflammatory response. Each included patient will received the Septicyte LAB test before and after surgery for acute mesenteric ischemia suspicion. The results will be compared to standard of care, retrospectively.

  • Septicyte Lab Test post operativeDevice

    SeptiCyte® technology uses proprietary biomarker signatures to assess the response of a patient's immune system to infections. It provides a score which can be used to differentiate sepsis from systemic inflammatory response. Each included patient will received the Septicyte LAB test before and after surgery for acute mesenteric ischemia suspicion. The results will be compared to standard of care, retrospectively.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Presence or absence of bacterial coinfection during acute mesenteric ischemiaTime frame: Day 0 (pre operative)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • CHRU de Nancy

    Nancy, Lorraine, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.